109 related articles for article (PubMed ID: 8008453)
1. Ricin-resistant mutants of Leishmania major which express modified lipophosphoglycan remain infective for mice.
Cappai R; Morris L; Aebischer T; Bacic A; Curtis JM; Kelleher M; McLeod KS; Moody SF; Osborn AH; Handman E
Parasitology; 1994 May; 108 ( Pt 4)():397-405. PubMed ID: 8008453
[TBL] [Abstract][Full Text] [Related]
2. Lipophosphoglycan expression and virulence in ricin-resistant variants of Leishmania major.
Elhay M; Kelleher M; Bacic A; McConville MJ; Tolson DL; Pearson TW; Handman E
Mol Biochem Parasitol; 1990 May; 40(2):255-67. PubMed ID: 2362605
[TBL] [Abstract][Full Text] [Related]
3. Characterization of lipophosphoglycan from a ricin-resistant mutant of Leishmania major.
Opat A; Ng K; Currie G; Handman E; Bacic A
Glycobiology; 1996 Jun; 6(4):387-97. PubMed ID: 8842702
[TBL] [Abstract][Full Text] [Related]
4. Lipophosphoglycan is not required for infection of macrophages or mice by Leishmania mexicana.
Ilg T
EMBO J; 2000 May; 19(9):1953-62. PubMed ID: 10790362
[TBL] [Abstract][Full Text] [Related]
5. Characterization of a ricin-resistant mutant of Leishmania donovani that expresses lipophosphoglycan.
Phillips MR; Turco SJ
Glycobiology; 2015 Apr; 25(4):428-37. PubMed ID: 25472443
[TBL] [Abstract][Full Text] [Related]
6. Reversion to virulence in Leishmania major correlates with expression of surface lipophosphoglycan.
Shankar A; Mitchen TK; Hall LR; Turco SJ; Titus RG
Mol Biochem Parasitol; 1993 Oct; 61(2):207-16. PubMed ID: 8264725
[TBL] [Abstract][Full Text] [Related]
7. Complement-mediated lysis and infectivity for mouse macrophages and sandflies of virulent and attenuated Leishmania major promastigotes varying in expression of the major surface protease and lipophosphoglycan.
Camara M; Ortiz G; Valero PL; Molina R; Navarro I; Chance ML; Segovia M
Ann Trop Med Parasitol; 1995 Jun; 89(3):243-51. PubMed ID: 7668915
[TBL] [Abstract][Full Text] [Related]
8. A lipophosphoglycan-independent method for isolation of infective Leishmania metacyclic promastigotes by density gradient centrifugation.
Späth GF; Beverley SM
Exp Parasitol; 2001 Oct; 99(2):97-103. PubMed ID: 11748963
[TBL] [Abstract][Full Text] [Related]
9. Identification of a compensatory mutant (lpg2-REV) of Leishmania major able to survive as amastigotes within macrophages without LPG2-dependent glycoconjugates and its significance to virulence and immunization strategies.
Späth GF; Lye LF; Segawa H; Turco SJ; Beverley SM
Infect Immun; 2004 Jun; 72(6):3622-7. PubMed ID: 15155672
[TBL] [Abstract][Full Text] [Related]
10. Lipophosphoglycan is a virulence factor distinct from related glycoconjugates in the protozoan parasite Leishmania major.
Späth GF; Epstein L; Leader B; Singer SM; Avila HA; Turco SJ; Beverley SM
Proc Natl Acad Sci U S A; 2000 Aug; 97(16):9258-63. PubMed ID: 10908670
[TBL] [Abstract][Full Text] [Related]
11. Leishmania promastigotes require lipophosphoglycan to actively modulate the fusion properties of phagosomes at an early step of phagocytosis.
Dermine JF; Scianimanico S; Privé C; Descoteaux A; Desjardins M
Cell Microbiol; 2000 Apr; 2(2):115-26. PubMed ID: 11207568
[TBL] [Abstract][Full Text] [Related]
12. Leishmania expressed lipophosphoglycan interacts with Toll-like receptor (TLR)-2 to decrease TLR-9 expression and reduce anti-leishmanial responses.
Srivastava S; Pandey SP; Jha MK; Chandel HS; Saha B
Clin Exp Immunol; 2013 Jun; 172(3):403-9. PubMed ID: 23600828
[TBL] [Abstract][Full Text] [Related]
13. Virulent and attenuated lines of Leishmania major: DNA karyotypes and differences in metalloproteinase GP63.
Sádlová J; Volf P; Victoir K; Dujardin JC; Votýpka J
Folia Parasitol (Praha); 2006 Jun; 53(2):81-90. PubMed ID: 16898121
[TBL] [Abstract][Full Text] [Related]
14. A ricin agglutinin-resistant clone of Leishmania donovani deficient in lipophosphoglycan.
King DL; Turco SJ
Mol Biochem Parasitol; 1988 Apr; 28(3):285-93. PubMed ID: 3386685
[TBL] [Abstract][Full Text] [Related]
15. Targeted gene deletion of Leishmania major genes encoding developmental stage-specific leishmanolysin (GP63).
Joshi PB; Sacks DL; Modi G; McMaster WR
Mol Microbiol; 1998 Feb; 27(3):519-30. PubMed ID: 9489664
[TBL] [Abstract][Full Text] [Related]
16. Kinetics of entry of virulent and avirulent strains of Leishmania donovani into macrophages: a possible role of virulence molecules (gp63 and LPG).
Chakrabarty R; Mukherjee S; Lu HG; McGwire BS; Chang KP; Basu MK
J Parasitol; 1996 Aug; 82(4):632-5. PubMed ID: 8691373
[TBL] [Abstract][Full Text] [Related]
17. Golgi-located NTPDase1 of Leishmania major is required for lipophosphoglycan elongation and normal lesion development whereas secreted NTPDase2 is dispensable for virulence.
Sansom FM; Ralton JE; Sernee MF; Cohen AM; Hooker DJ; Hartland EL; Naderer T; McConville MJ
PLoS Negl Trop Dis; 2014 Dec; 8(12):e3402. PubMed ID: 25521752
[TBL] [Abstract][Full Text] [Related]
18. Toll-like receptor 2 (TLR2) plays a role in controlling cutaneous leishmaniasis in vivo, but does not require activation by parasite lipophosphoglycan.
Halliday A; Bates PA; Chance ML; Taylor MJ
Parasit Vectors; 2016 Oct; 9(1):532. PubMed ID: 27716391
[TBL] [Abstract][Full Text] [Related]
19. Leishmania major: a clone with low virulence for BALB/c mice elicits a Th1 type response and protects against infection with a highly virulent clone.
Li J; Nolan TJ; Farrell JP
Exp Parasitol; 1997 Sep; 87(1):47-57. PubMed ID: 9287957
[TBL] [Abstract][Full Text] [Related]
20. Structure of Leishmania lipophosphoglycan: inter- and intra-specific polymorphism in Old World species.
McConville MJ; Schnur LF; Jaffe C; Schneider P
Biochem J; 1995 Sep; 310 ( Pt 3)(Pt 3):807-18. PubMed ID: 7575413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
